Nath Bio-Genes (India) Ltd (BOM:537291)
₹ 216.15 -0.85 (-0.39%) Market Cap: 4.11 Bil Enterprise Value: 4.44 Bil PE Ratio: 10.33 PB Ratio: 0.67 GF Score: 71/100

Q4 2024 Nath Bio-Genes (I) Ltd Earnings Call Transcript

May 09, 2024 / 10:30AM GMT
Release Date Price: ₹193.7 (-5.19%)

Key Points

Positve
  • Nath Bio-Genes (India) Ltd (BOM:537291) reported a 10.43% increase in top-line revenue for FY24, reaching INR332 crores.
  • The company's gross margin exceeded 55% during the year, maintaining a strong financial performance.
  • Profit after tax increased by 16.8% to INR411 million, showcasing robust profitability.
  • The company maintained a zero long-term debt position, reflecting strong financial health.
  • Nath Bio-Genes (India) Ltd (BOM:537291) continues to invest in R&D, resulting in innovative products and high-performance seeds that benefit farmers.
Negative
  • The company faces challenges in seed production due to fluctuating monsoons and a shortage of farm labor.
  • There is an overall shortage of cotton seeds in the industry, which may impact supply and sales.
  • Geopolitical uncertainties are affecting the company's efforts to expand in certain international markets, particularly in Africa.
  • Illegal BT cotton in the market poses a competitive threat and impacts sales.
  • The working capital cycle, although improving, still requires careful management to maintain positive operational cash flow.
Operator

Ladies and gentlemen, good day, and welcome to the Q4 FY24 earnings conference call of Nath Bio-Genes, hosted by Go India Advisors. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Deepika Sharma from Go India Advisors. Thank you and over to you, ma'am.

Deepika Sharma;Satish Kagliwal
Go India Advisors - Investor Relations

Thank you, Mukhan. Good afternoon, everyone, and welcome to the Q4 FY24 earnings call of Nath Bio-Genes Limited. We have on the call Mr. Satish Kagliwal, Managing Director; Mr. Devinder Khurana, Chief Financial Officer; Mr. Harish Pandey, Business Lead; Dr. Venkatesh Kulkarni, Research Lead. We must remind you that the discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risk that company faces.

May I now request the management to take us through the financials and the business outlook subsequent to which we will open the floor for Q&A. Thank you, and over to you, sir.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot